European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Ascendis Pharma Price Target Raised to $200.00/Share From $168.00 by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Top Gap Ups and Downs on Monday: NFLX, NVO, NVS and More
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $162
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Why Is BioMarin Stock Trading Higher On Thursday?
Express News | Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 6.01 Million in Common Stocks
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $180 to $289
Express News | Ascendis Pharma Shares Are Trading Higher After Evercore ISI Raised Its Price Target on the Stock From $220 to $260
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading